This HTML5 document contains 117 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://dx.doi.org/10.1038/
n13http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10https://scigraph.springernature.com/pub.10.1038/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q42843110
rdf:type
wikibase:Item
schema:description
2010年论文 artigo científico מאמר מדעי tudományos cikk vědecký článek vitskapeleg artikkel scientific article published on 23 February 2010 სამეცნიერო სტატია article scientific 2010年論文 2010년 논문 vetenskaplig artikel articol științific scienca artikolo article científic 2010年論文 ২৩ ফেব্রুয়ারি ২০১০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ artikull shkencor 2010年论文 bilimsel makale artykuł naukowy مقالة علمية نشرت في 23 فبراير 2010 vedecký článok научная статья wissenschaftlicher Artikel artikel ilmiah 2010年论文 artigo científico мақолаи илмӣ wetenschappelijk artikel 2010年論文 научни чланак наукова стаття, опублікована в лютому 2010 scientific article published on 23 February 2010 2010年论文 artículu científicu espublizáu en 2010 บทความทางวิทยาศาสตร์ 2010年の論文 artigo científico 2010年论文 научни чланак articolo scientifico videnskabelig artikel научна статия naučni članak 2010年論文 επιστημονικό άρθρο article scientifique vitenskapelig artikkel scientific article published on 23 February 2010 artículo científico publicado en 2010 2010年論文 teaduslik artikkel bài báo khoa học 2010年论文 artikulong pang-agham tieteellinen artikkeli 2010 nî lūn-bûn
p:P577
wds:Q42843110-3BB9FBFB-7A95-43AA-B6D4-CB0521F5FA00
wdt:P577
2010-02-23T00:00:00Z
p:P407
wds:Q42843110-1193E1CE-0F79-4F60-B47A-8591AF31E9E1
wdt:P407
wd:Q1860
p:P2888
wds:Q42843110-87B99FA1-E65B-4C7D-8394-BE0EA732659C
wdt:P2888
n10:sj.bjc.6605585
p:P2860
wds:Q42843110-AB5DB55F-CF04-477D-8B04-0939B7931F3E wds:Q42843110-CC1C0911-8EE6-447B-B6BF-78C30908B6DC wds:Q42843110-082A174F-5487-4E06-9126-DEC31E65779A wds:Q42843110-13AD93CE-999D-4CDC-94E8-FF49C38546C7 wds:Q42843110-26A2573E-0A4C-407D-A61F-3455DC62AFAB wds:Q42843110-5061A730-21FA-44F0-B525-6FBFF2A59B32 wds:Q42843110-63C31F91-71C7-4032-9B39-112274D302CB wds:Q42843110-94971545-4DAD-4712-96E6-5C7E9B591975
wdt:P2860
wd:Q34586436 wd:Q79484124 wd:Q37451860 wd:Q37427388 wd:Q81071045 wd:Q28282757 wd:Q45993980 wd:Q33387073
rdfs:label
Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'. Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.
skos:prefLabel
Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'. Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.
schema:name
Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'. Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.
p:P50
wds:Q42843110-591706C1-1747-4C3E-91E0-9EF872EE8BF5
wdt:P50
wd:Q37393105
p:P1476
wds:Q42843110-E624B87B-A138-4B57-8133-0F76CE38F132
wdt:P1476
Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.
p:P304
wds:Q42843110-B0103EB7-F941-4589-93DB-530098016305
wdt:P304
1196-1197
p:P31
wds:Q42843110-B1F54B23-CC5E-46FB-90B5-9439CC116809
wdt:P31
wd:Q13442814
p:P921
wds:Q42843110-B4B3825D-E477-4091-A6FE-38687FB7EAB5 wds:Q42843110-9CF8A38D-99AA-40F8-990C-79EF97420438 wds:Q42843110-A69A18A8-71C7-47DA-B9B6-D3AFD68F1FF0
wdt:P921
wd:Q413299 wd:Q1164529 wd:Q19000948
p:P698
wds:Q42843110-DF4FD05E-64D3-4EFB-95A8-06D8846FCA74
wdtn:P698
n13:20179707
wdt:P698
20179707
p:P1433
wds:Q42843110-819A92BF-4E69-43B4-BF9A-552686C5CDBD
wdt:P1433
wd:Q326309
p:P433
wds:Q42843110-06EE590A-CD97-401F-B568-8846225BCF9F
p:P478
wds:Q42843110-604E8C68-9A44-45F4-AD07-07405821620D
wdt:P433
7
wdt:P478
102
p:P356
wds:Q42843110-4DE0F703-9BC2-4C84-90C7-B8D148BADEE5
wdtn:P356
n12:SJ.BJC.6605585
wdt:P356
10.1038/SJ.BJC.6605585
p:P5875
wds:Q42843110-951E30CB-9537-4949-A4DE-E91BACB4496B
wdt:P5875
41548758
p:P932
wds:Q42843110-CFD14AE7-F491-4BC5-8858-91B98E2FD1A1
wdt:P932
2853087